ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Efficacy and safety of selpercatinib in Chinese patients with advanced RET-altered thyroid cancers: results from the phase II LIBRETTO-321 study

Zheng, Xiangqian; Ji, Qinghai; Sun, Yuping; Ge, Minghua; Zhang, Bin; Cheng, Ying; Lei, Shangtong; Shi, Feng; Guo, Ye; Li, Linfa; Chen, Lu; Shao, Jingxin; Zhang, Wanli; Gao, Ming*复旦大学; 北京大学; 南方医科大学; 山东大学; 同济大学
Therapeutic Advances in Medical Oncology2022-8DOI: 10.1177/17588359221119318
7被引20阅读
引用收藏
分享

摘要

Background: Selpercatinib, a highly selective and potent REarranged during Transfection (RET) kinase inhibitor, is effective in advanced RET-altered thyroid cancer (TC). However, the efficacy and safety in Chinese patients are unknown. Patients and methods: In the open-label, multi-center phase II LIBRETTO-321 (NCT04280081) study, Chinese patients with advanced solid tumors harboring RET alterations received selpercatinib 160 mg twice daily. The primary endpoint was objective response rate (ORR; RECIST v1.1) by independent review committee (IRC). Secondary endpoints included duration of response (DoR) and safety. Efficacy was assessed in the primary analysis set [PAS; treated patients with RET fusion-positive TC or RET-mutant medullary TC (MTC) confirmed by central laboratory] and all enrolled patients with MTC. Results: Of 77 enrolled patients, 29 had RET-mutant MTC and one had RET fusion-positive TC. In the PAS (n = 26), the ORR by IRC was 57.7% [95% confidence interval (CI), 36.9-76.6]. Median DoR was not reached and 93.3% of responses were ongoing at a median follow-up of 8.7 months. In all enrolled MTC patients (n = 29), the ORR by IRC was 58.6% (95% CI, 38.9-76.5). One RET fusion-positive TC patient treated for 23.4 weeks achieved a partial response at week 8 that was ongoing at cutoff. In the safety population (n = 77), 59.7% experienced grade > 3 treatment-emergent adverse events (TEAEs). TEAEs led to dose reductions in 32.5% (n = 25) and discontinuations in 5.2% [n = 4; 3.9% (n = 3) considered treatment related] of patients. Conclusions: Selpercatinib showed robust antitumor activity and was well tolerated in Chinese patients with advanced RET-altered TC, consistent with global data from LIBRETTO-001 (NCT04280081). ClinicalTrials.gov Identifier: NCT04280081 (first posted Feb 21, 2020)

学科与关键词

关键词
AsianRET fusionRET kinase inhibitorRET mutantSelpercatinibthyroid cancer
相关
加载中…
  • LIBRETTO-321, a phase II study of the efficacy and safety of selpercatinib in Chinese patients with advanced RET-altered thyroid cancer (TC)
    Zheng, X.; Ji, Q.; Sun, Y.; Ge, M.; Zhang, B.; Cheng, Y.; Lei, S.; Shi, F.; Zhang, W.; Gao, M.ESMO Targeted Anticancer Therapies Congress (TAT), ELECTR NETWORK, 2022-03-07 To 2022-03-08.被引 1
  • A phase I study of KL590586, a next-generation selective RET inhibitor, in patients with RET-altered solid tumors
    Zhou, Qing; Wu, Yi-Long; Zheng, Xiangqian; Li, Dapeng; Huang, Dingzhi; Li, Xingya; Liu, Anwen; Song, Xia; Jing, Shanghua; Wang, Mingxia; Wang, Xicheng; Luo, Yongzhong; Song, Yong; Mi, Yanjun; Zhou, Jianying; Fan, Yun; Su, Haichuan; Huang, Tao; Ouyang, Weiwei; Ge, JunyouAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 2023-06-02 To 2023-06-06.
  • Anlotinib in patients with medullary thyroid carcinoma with negative prognostic factors: A sub-analysis based on the ALTER01031 study
    Zhao, Jingzhu; Chi, Yihebali; Hu, Chuanxiang; Chen, Xiaohong; Ge, Minghua; Zhang, Yuan; Guo, Zhuming; Wang, Jun; Chen, Jie; Zhang, Jiewu; Cheng, Ying; Li, Zhendong; Liu, Hui; Qin, Jianwu; Zhu, Jingqiang; Cheng, Ruochuan; Xu, Zhengang; Li, Dapeng; Tang, Pingzhang; Gao, Ming*; Zheng, Xiangqian*Frontiers in Oncology, 2022, 12: 852032.被引 2
查看全部 →

发表信息

论文状态
公开发表
期刊
Therapeutic Advances in Medical Oncology
发表日期
2022-08
卷期
第 14 卷
页码
17588359221119318
DOI
10.1177/17588359221119318
语言
ENGLISH
期刊等级
2区
成果收录
SCIE
资助标注
Eli Lilly and Company

作者

  • Z

    Zheng, Xiangqian (第一作者)

    tianjin med univ

  • J

    Ji, Qinghai

    fudan univ

查看全部 14 位作者收起作者
  • S

    Sun, Yuping

    jinan cent hosp · shandong univ

  • G

    Ge, Minghua

    zhejiang prov peoples hosp

  • Z

    Zhang, Bin

    peking univ

  • C

    Cheng, Ying

  • L

    Lei, Shangtong

    southern med univ

  • S

    Shi, Feng

    hunan canc hosp

  • G

    Guo, Ye

    tongji univ

  • L

    Li, Linfa

    zhejiang canc hosp

  • C

    Chen, Lu

  • S

    Shao, Jingxin

  • Z

    Zhang, Wanli

  • G

    Gao, Ming (通讯)

    tianjin med univ · tianjin union med ctr

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417